There are novel insights into the genetic basis of the GC action diversity that point to an important role for GC receptor (GR) gene polymorphisms, suggesting a possible modulation in occurrence of metabolic disorders, what may be relevant to clinical management of 21-OHD. This evidence concerns the gene NR3C1 and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.